Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

第1/2相 実施中（募集終了） NCT04216316

概要

This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung cancer that has spared to other placed in the body (advanced). Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving berzosertib together with carboplatin, gemcitabine, and pembrolizumab may work better in treating patients with squamous cell non-small cell lung cancer compared to carboplatin, gemcitabine, and pembrolizumab alone.

Patients Who Experienced a DLT

Up to completion of cycle 1 · percentage of patients

Recommended Phase 2 Dose (RP2D)

Up to completion of cycle 1 · mg/mL*min

12-month Progression-free Survival (PFS) - Total Population

At 12 months · percentage of patients

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
• Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
• Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
• Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
• Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
• A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC

すべての治験